Canakinumab reduces cardiovascular risk - Novartis

Phase 3 trial results of canakinumab (Ilaris), a monoclonal antibody that targets interleukin 1 beta (IL-1 beta), have shown a significant 15% reduction of major cardiovascular events in people with a prior heart attack and inflammatory atherosclerosis.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Switzerland